These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 35706413)

  • 1. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
    Alvarez-Breckenridge C; Markson SC; Stocking JH; Nayyar N; Lastrapes M; Strickland MR; Kim AE; de Sauvage M; Dahal A; Larson JM; Mora JL; Navia AW; Klein RH; Kuter BM; Gill CM; Bertalan M; Shaw B; Kaplan A; Subramanian M; Jain A; Kumar S; Danish H; White M; Shahid O; Pauken KE; Miller BC; Frederick DT; Hebert C; Shaw M; Martinez-Lage M; Frosch M; Wang N; Gerstner E; Nahed BV; Curry WT; Carter B; Cahill DP; Boland GM; Izar B; Davies MA; Sharpe AH; Suvà ML; Sullivan RJ; Brastianos PK; Carter SL
    Cancer Immunol Res; 2022 Aug; 10(8):996-1012. PubMed ID: 35706413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
    Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
    Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases.
    Fischer GM; Jalali A; Kircher DA; Lee WC; McQuade JL; Haydu LE; Joon AY; Reuben A; de Macedo MP; Carapeto FCL; Yang C; Srivastava A; Ambati CR; Sreekumar A; Hudgens CW; Knighton B; Deng W; Ferguson SD; Tawbi HA; Glitza IC; Gershenwald JE; Vashisht Gopal YN; Hwu P; Huse JT; Wargo JA; Futreal PA; Putluri N; Lazar AJ; DeBerardinis RJ; Marszalek JR; Zhang J; Holmen SL; Tetzlaff MT; Davies MA
    Cancer Discov; 2019 May; 9(5):628-645. PubMed ID: 30787016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Sequencing Radiation Therapy and Immune Checkpoint Inhibitors in the Treatment of Melanoma Brain Metastases.
    Pomeranz Krummel DA; Nasti TH; Izar B; Press RH; Xu M; Lowder L; Kallay L; Rupji M; Rosen H; Su J; Curran W; Olson J; Weinberg B; Schniederjan M; Neill S; Lawson D; Kowalski J; Khan MK; Sengupta S
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):157-163. PubMed ID: 32057994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of systemic therapy in melanoma brain metastases: a narrative review.
    Saleem K; Davar D
    Chin Clin Oncol; 2022 Jun; 11(3):24. PubMed ID: 35818856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA).
    Hassel JC; Schank TE; Smetak H; Mühlbauer J; Salzmann M; Machiraju D; Menzer C; Lang K; König L; Haefner MF; Hülsmeyer I; Kohler C; Spang R; Enk A; Debus J; Beckhove P
    Oncoimmunology; 2022; 11(1):2066609. PubMed ID: 35481285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single-Cell Characterization of the Immune Microenvironment of Melanoma Brain and Leptomeningeal Metastases.
    Smalley I; Chen Z; Phadke M; Li J; Yu X; Wyatt C; Evernden B; Messina JL; Sarnaik A; Sondak VK; Zhang C; Law V; Tran N; Etame A; Macaulay RJB; Eroglu Z; Forsyth PA; Rodriguez PC; Chen YA; Smalley KSM
    Clin Cancer Res; 2021 Jul; 27(14):4109-4125. PubMed ID: 34035069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the systemic treatment of melanoma brain metastases.
    Glitza Oliva IC; Schvartsman G; Tawbi H
    Ann Oncol; 2018 Jul; 29(7):1509-1520. PubMed ID: 29790899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
    Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
    Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes of melanoma brain metastases treated with nivolumab and ipilimumab alone versus nivolumab and ipilimumab with stereotactic radiosurgery.
    Tang JD; Mills MN; Nakashima J; Dohm AE; Khushalani NI; Forsyth PA; Vogelbaum MA; Wuthrick EJ; Yu HM; Oliver DE; Liu JKC; Ahmed KA
    J Neurooncol; 2024 Feb; 166(3):431-440. PubMed ID: 38310157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan.
    Wada S; Ogata D; Kashihara T; Okuma K; Eto H; Nakano E; Takahashi A; Namikawa K; Igaki H; Yamazaki N
    Cancer Med; 2023 Dec; 12(24):21933-21943. PubMed ID: 38083908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chidamide plus Tyrosine Kinase Inhibitor Remodel the Tumor Immune Microenvironment and Reduce Tumor Progression When Combined with Immune Checkpoint Inhibitor in Naïve and Anti-PD-1 Resistant CT26-Bearing Mice.
    Chen JS; Hsieh YC; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142591
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting the treatment-naive ecosystem of human melanoma brain metastasis.
    Biermann J; Melms JC; Amin AD; Wang Y; Caprio LA; Karz A; Tagore S; Barrera I; Ibarra-Arellano MA; Andreatta M; Fullerton BT; Gretarsson KH; Sahu V; Mangipudy VS; Nguyen TTT; Nair A; Rogava M; Ho P; Koch PD; Banu M; Humala N; Mahajan A; Walsh ZH; Shah SB; Vaccaro DH; Caldwell B; Mu M; Wünnemann F; Chazotte M; Berhe S; Luoma AM; Driver J; Ingham M; Khan SA; Rapisuwon S; Slingluff CL; Eigentler T; Röcken M; Carvajal R; Atkins MB; Davies MA; Agustinus A; Bakhoum SF; Azizi E; Siegelin M; Lu C; Carmona SJ; Hibshoosh H; Ribas A; Canoll P; Bruce JN; Bi WL; Agrawal P; Schapiro D; Hernando E; Macosko EZ; Chen F; Schwartz GK; Izar B
    Cell; 2022 Jul; 185(14):2591-2608.e30. PubMed ID: 35803246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET receptor serves as a promising target in melanoma brain metastases.
    Redmer T; Schumann E; Peters K; Weidemeier ME; Nowak S; Schroeder HWS; Vidal A; Radbruch H; Lehmann A; Kreuzer-Redmer S; Jürchott K; Radke J
    Acta Neuropathol; 2024 Feb; 147(1):44. PubMed ID: 38386085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
    Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice.
    Jablonska PA; Fong CH; Kruser T; Weiss J; Liu ZA; Takami H; Narita Y; Ynoe de Moraes F; Dasgupta A; Ong CK; Yang JCH; Lee JH; Pavlakis N; Kongkham P; Butler M; Shultz DB
    Radiother Oncol; 2022 Mar; 168():89-94. PubMed ID: 35121033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
    Lau PKH; Feran B; Smith L; Lasocki A; Molania R; Smith K; Weppler A; Angel C; Kee D; Bhave P; Lee B; Young RJ; Iravani A; Yeang HA; Vergara IA; Kok D; Drummond K; Neeson PJ; Sheppard KE; Papenfuss T; Solomon BJ; Sandhu S; McArthur GA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade.
    Genova C; Dellepiane C; Carrega P; Sommariva S; Ferlazzo G; Pronzato P; Gangemi R; Filaci G; Coco S; Croce M
    Front Immunol; 2021; 12():799455. PubMed ID: 35069581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities.
    Karz A; Dimitrova M; Kleffman K; Alvarez-Breckenridge C; Atkins MB; Boire A; Bosenberg M; Brastianos P; Cahill DP; Chen Q; Ferguson S; Forsyth P; Glitza Oliva IC; Goldberg SB; Holmen SL; Knisely JPS; Merlino G; Nguyen DX; Pacold ME; Perez-Guijarro E; Smalley KSM; Tawbi HA; Wen PY; Davies MA; Kluger HM; Mehnert JM; Hernando E
    Pigment Cell Melanoma Res; 2022 Nov; 35(6):554-572. PubMed ID: 35912544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
    Sloot S; Chen YA; Zhao X; Weber JL; Benedict JJ; Mulé JJ; Smalley KS; Weber JS; Zager JS; Forsyth PA; Sondak VK; Gibney GT
    Cancer; 2018 Jan; 124(2):297-305. PubMed ID: 29023643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.